Investment opportunity
Adult stem cell specialist EpiStem Ltd, of Manchester, UK, is to float on the Alternative Investment Market in London, raising £3 million.
The company is developing its adult stem cell lines for use in oncology and gastrointestinal diseases and for cosmetic applications. It is also applying its expertise in the regulation of adult stem cells located in epithelial tissues to the discovery of diagnostic biomarkers.
In addition, it operates a drug discovery services arm, proving preclinical efficacy testing.
Through its discovery platform EpiStem says it has identified 250 potential drug candidates, a subset of which will be evaluated as stem cell regulators.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
